Molecular techniques are growing by leaps and bounds, and the market is ripe for disruption.   

The advent of COVID has created many new opportunities for companies that are looking to deliver faster and more accurate results. As we move into the future of medicine, we need to ask: What does this mean for our industry?  

In this episode we sit down with Elijah Onyimi to tackle this question and more.